Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [2][4]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements about the progress of its prostate cancer therapeutic candidates [4]. - It is claimed that Telix materially overstated the quality of its supply chain and partners, resulting in misleading statements about its business operations and prospects [4]. - The lawsuit asserts that when the true details about Telix's situation became public, investors suffered damages [4]. Group 2: Impact on Stock Price - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission regarding Telix's disclosures, the price of Telix's American Depositary Shares fell more than 13% over two trading sessions [5]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which identified deficiencies in its product TLX250-CDx, causing the stock price to drop more than 21% over two trading sessions [6]. Group 3: Legal Proceedings - Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is a deadline of January 9, 2026, for investors to seek the role of lead plaintiff in the federal securities class action against Telix [2][7].
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals